Diferencia entre revisiones de «Template:Meningitis Antibiotics»
Sin resumen de edición |
|||
| Línea 1: | Línea 1: | ||
====Guidelines:<ref>van de Beek D. et al. Advances in treatment of bacterial meningitis. Lancet. Nov 10 2012;380(9854):1693-702</ref>==== | ====Guidelines:<ref>van de Beek D. et al. Advances in treatment of bacterial meningitis. Lancet. Nov 10 2012;380(9854):1693-702</ref>==== | ||
;Age 18-50y | ;Age 18-50y | ||
*[[Ceftriaxone]] 2gm IV q12hr + [[vancomycin]] 15mg/kg q8-12hr | |||
**([[vancomycin]] is for resistant [[pneumococcus]]) | |||
;Age >50y | ;Age >50y | ||
*[[Ceftriaxone]] 2gm IV q12hr + [[vancomycin]] 15mg/kg q8-12hr + [[ampicillin]] 2gm IV q4h | |||
;CSF leak with closed head trauma | ;CSF leak with closed head trauma | ||
*[[Ceftriaxone]] 2gm IV q12hr + [[vancomycin]] 15mg/kg q8-12hr | |||
;Penetrating head injury (or recent surgery) | ;Penetrating head injury (or recent surgery) | ||
*([[Ceftazidime]] 2gm IV q8hr or [[cefepime]] or [[meropenem]]) + [[vanco]] 25 milligrams/kg load | |||
;Meningitis due to [[Sinusitis]] | ;Meningitis due to [[Sinusitis]] | ||
*[[Ceftriaxone]] + [[Metronidazole]] | |||
;Meningitis with severe PCN allergy | ;Meningitis with severe PCN allergy | ||
*[[Chloramphenicol]] 1g IV q6h + [[vancomycin]] 15mg/kg q8-12hr | |||
Revisión del 20:11 24 feb 2015
Guidelines:[1]
- Age 18-50y
- Ceftriaxone 2gm IV q12hr + vancomycin 15mg/kg q8-12hr
- (vancomycin is for resistant pneumococcus)
- Age >50y
- Ceftriaxone 2gm IV q12hr + vancomycin 15mg/kg q8-12hr + ampicillin 2gm IV q4h
- CSF leak with closed head trauma
- Ceftriaxone 2gm IV q12hr + vancomycin 15mg/kg q8-12hr
- Penetrating head injury (or recent surgery)
- (Ceftazidime 2gm IV q8hr or cefepime or meropenem) + vanco 25 milligrams/kg load
- Meningitis due to Sinusitis
- Meningitis with severe PCN allergy
- Chloramphenicol 1g IV q6h + vancomycin 15mg/kg q8-12hr
- ↑ van de Beek D. et al. Advances in treatment of bacterial meningitis. Lancet. Nov 10 2012;380(9854):1693-702